Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2020

20.07.2020 | Epidemiology

Financial toxicity and contralateral prophylactic mastectomy: an analysis using propensity score methods

verfasst von: Malke Asaad, Stefanos Boukovalas, Carrie K. Chu, Yu-Li Lin, Cristina M. Checka, Mark W. Clemens, Rachel A. Greenup, Anaeze C. Offodile II

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Contralateral prophylactic mastectomy (CPM) is increasingly performed in average-risk patients despite the lack of survival benefit. In an era of heightened awareness of healthcare costs, we sought to determine the impact of CPM on financial toxicity in breast cancer.

Methods

A single-institution propensity-matched analysis of female patients who underwent unilateral mastectomy (UM) with or without CPM for breast cancer over an 18-month period. Patients with a history of genetic predisposition or bilateral cancer were excluded. The validated Comprehensive Score for financial Toxicity (COST) evaluated financial toxicity among participants. Multivariable regression analysis evaluated the relationship between CPM and financial toxicity. Relevant domains of the Breast Q and SF12 instruments were examined as secondary outcomes. Sensitivity analysis was performed using propensity-weighting to examine robustness of results and increase our sample size.

Results

Overall, 104 patients were identified, equally distributed across UM and CPM. CPM was not associated with financial toxicity, as evidenced by comparable COST scores (adjusted difference, 1.53 [− 3.24 to 6.29]). Minor complications were significantly lower in UM patients (UM, 8%; CPM, 31%). CPM was associated with significantly higher Breast Q psychosocial well-being score (adjusted difference, 10.58 [1.34 to 19.83]). BREAST Q surgeon satisfaction, SF12 mental and physical component scores were comparable. Similar results were noted on sensitivity analysis involving 194 patients.

Conclusions

Choice for CPM was associated with higher minor complications, but led to improved psychosocial well-being without a higher degree of patient-reported financial toxicity. Prospective studies are needed to discern the influence of CPM on the incidence and trajectory of financial toxicity.
Literatur
1.
Zurück zum Zitat Tuttle TM, Habermann EB, Grund EH, Morris TJ, Virnig BA (2007) Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol 25:5203–5209PubMed Tuttle TM, Habermann EB, Grund EH, Morris TJ, Virnig BA (2007) Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol 25:5203–5209PubMed
2.
Zurück zum Zitat Tuttle TM, Jarosek S, Habermann EB et al (2009) Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ. J Clin Oncol 27:1362–1367PubMed Tuttle TM, Jarosek S, Habermann EB et al (2009) Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ. J Clin Oncol 27:1362–1367PubMed
3.
Zurück zum Zitat Wong SM, Freedman RA, Sagara Y, Aydogan F, Barry WT, Golshan M (2017) Growing use of contralateral prophylactic mastectomy despite no improvement in long-term survival for invasive breast cancer. Ann Surg 265:581–589PubMed Wong SM, Freedman RA, Sagara Y, Aydogan F, Barry WT, Golshan M (2017) Growing use of contralateral prophylactic mastectomy despite no improvement in long-term survival for invasive breast cancer. Ann Surg 265:581–589PubMed
4.
Zurück zum Zitat Nichols HB, Berrington de González A, Lacey JV Jr, Rosenberg PS, Anderson WF (2011) Declining incidence of contralateral breast cancer in the United States from 1975 to 2006. J Clin Oncol 29:1564–1569PubMedPubMedCentral Nichols HB, Berrington de González A, Lacey JV Jr, Rosenberg PS, Anderson WF (2011) Declining incidence of contralateral breast cancer in the United States from 1975 to 2006. J Clin Oncol 29:1564–1569PubMedPubMedCentral
5.
Zurück zum Zitat Dores GM, Anderson WF, Beane Freeman LE, Fraumeni JF Jr, Curtis RE (2010) Risk of breast cancer according to clinicopathologic features among long-term survivors of Hodgkin's lymphoma treated with radiotherapy. Br J Cancer 103:1081–1084PubMedPubMedCentral Dores GM, Anderson WF, Beane Freeman LE, Fraumeni JF Jr, Curtis RE (2010) Risk of breast cancer according to clinicopathologic features among long-term survivors of Hodgkin's lymphoma treated with radiotherapy. Br J Cancer 103:1081–1084PubMedPubMedCentral
6.
Zurück zum Zitat Giuliano AE, Boolbol S, Degnim A, Kuerer H, Leitch AM, Morrow M (2007) Society of surgical oncology: position statement on prophylactic mastectomy. approved by the society of surgical oncology executive council, March 2007. Ann Surg Oncol 14:2425–2427PubMed Giuliano AE, Boolbol S, Degnim A, Kuerer H, Leitch AM, Morrow M (2007) Society of surgical oncology: position statement on prophylactic mastectomy. approved by the society of surgical oncology executive council, March 2007. Ann Surg Oncol 14:2425–2427PubMed
7.
Zurück zum Zitat Metcalfe K, Lynch HT, Ghadirian P et al (2004) Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 22:2328–2335PubMed Metcalfe K, Lynch HT, Ghadirian P et al (2004) Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 22:2328–2335PubMed
8.
Zurück zum Zitat Morrow M (2011) Prophylactic mastectomy of the contralateral breast. Breast 20:S108–S110PubMed Morrow M (2011) Prophylactic mastectomy of the contralateral breast. Breast 20:S108–S110PubMed
9.
Zurück zum Zitat Hawley ST, Jagsi R, Morrow M et al (2014) Social and clinical determinants of contralateral prophylactic mastectomy. JAMA Surg 149:582–589PubMedPubMedCentral Hawley ST, Jagsi R, Morrow M et al (2014) Social and clinical determinants of contralateral prophylactic mastectomy. JAMA Surg 149:582–589PubMedPubMedCentral
10.
Zurück zum Zitat Rosenberg SM, Tracy MS, Meyer ME et al (2013) Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: a cross-sectional survey. Ann Intern Med 159:373–381PubMedPubMedCentral Rosenberg SM, Tracy MS, Meyer ME et al (2013) Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: a cross-sectional survey. Ann Intern Med 159:373–381PubMedPubMedCentral
11.
Zurück zum Zitat Pesce C, Liederbach E, Wang C, Lapin B, Winchester DJ, Yao K (2014) Contralateral prophylactic mastectomy provides no survival benefit in young women with estrogen receptor-negative breast cancer. Ann Surg Oncol 21:3231–3239PubMed Pesce C, Liederbach E, Wang C, Lapin B, Winchester DJ, Yao K (2014) Contralateral prophylactic mastectomy provides no survival benefit in young women with estrogen receptor-negative breast cancer. Ann Surg Oncol 21:3231–3239PubMed
12.
Zurück zum Zitat Kurian AW, Lichtensztajn DY, Keegan TH, Nelson DO, Clarke CA, Gomez SL (2014) Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California, 1998–2011. JAMA 312:902–914PubMedPubMedCentral Kurian AW, Lichtensztajn DY, Keegan TH, Nelson DO, Clarke CA, Gomez SL (2014) Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California, 1998–2011. JAMA 312:902–914PubMedPubMedCentral
13.
Zurück zum Zitat Chung A, Huynh K, Lawrence C, Sim MS, Giuliano A (2012) Comparison of patient characteristics and outcomes of contralateral prophylactic mastectomy and unilateral total mastectomy in breast cancer patients. Ann Surg Oncol 19:2600–2606PubMed Chung A, Huynh K, Lawrence C, Sim MS, Giuliano A (2012) Comparison of patient characteristics and outcomes of contralateral prophylactic mastectomy and unilateral total mastectomy in breast cancer patients. Ann Surg Oncol 19:2600–2606PubMed
14.
Zurück zum Zitat Boughey JC, Attai DJ, Chen SL et al (2016) Contralateral prophylactic mastectomy consensus statement from the American Society of breast surgeons: additional considerations and a framework for shared decision making. Ann Surg Oncol 23:3106–3111PubMedPubMedCentral Boughey JC, Attai DJ, Chen SL et al (2016) Contralateral prophylactic mastectomy consensus statement from the American Society of breast surgeons: additional considerations and a framework for shared decision making. Ann Surg Oncol 23:3106–3111PubMedPubMedCentral
15.
Zurück zum Zitat Miller ME, Czechura T, Martz B et al (2013) Operative risks associated with contralateral prophylactic mastectomy: a single institution experience. Ann Surg Oncol 20:4113–4120PubMed Miller ME, Czechura T, Martz B et al (2013) Operative risks associated with contralateral prophylactic mastectomy: a single institution experience. Ann Surg Oncol 20:4113–4120PubMed
16.
Zurück zum Zitat Osman F, Saleh F, Jackson TD, Corrigan MA, Cil T (2013) Increased postoperative complications in bilateral mastectomy patients compared to unilateral mastectomy: an analysis of the NSQIP database. Ann Surg Oncol 20:3212–3217PubMed Osman F, Saleh F, Jackson TD, Corrigan MA, Cil T (2013) Increased postoperative complications in bilateral mastectomy patients compared to unilateral mastectomy: an analysis of the NSQIP database. Ann Surg Oncol 20:3212–3217PubMed
17.
Zurück zum Zitat Billig JI, Duncan A, Zhong L et al (2018) The cost of contralateral prophylactic mastectomy in women with unilateral breast cancer. Plast Reconstr Surg 141:1094–1102PubMedPubMedCentral Billig JI, Duncan A, Zhong L et al (2018) The cost of contralateral prophylactic mastectomy in women with unilateral breast cancer. Plast Reconstr Surg 141:1094–1102PubMedPubMedCentral
18.
Zurück zum Zitat Deshmukh AA, Cantor SB, Crosby MA et al (2014) Cost of contralateral prophylactic mastectomy. Ann Surg Oncol 21:2823–2830PubMedPubMedCentral Deshmukh AA, Cantor SB, Crosby MA et al (2014) Cost of contralateral prophylactic mastectomy. Ann Surg Oncol 21:2823–2830PubMedPubMedCentral
19.
Zurück zum Zitat Sharpe SM, Liederbach E, Czechura T, Pesce C, Winchester DJ, Yao K (2014) Impact of bilateral versus unilateral mastectomy on short term outcomes and adjuvant therapy, 2003–2010: a report from the National Cancer Data Base. Ann Surg Oncol 21:2920–2927PubMed Sharpe SM, Liederbach E, Czechura T, Pesce C, Winchester DJ, Yao K (2014) Impact of bilateral versus unilateral mastectomy on short term outcomes and adjuvant therapy, 2003–2010: a report from the National Cancer Data Base. Ann Surg Oncol 21:2920–2927PubMed
20.
Zurück zum Zitat Yao K, Sisco M, Bedrosian I (2016) Contralateral prophylactic mastectomy: current perspectives. Int J Womens Health 8:213–223PubMedPubMedCentral Yao K, Sisco M, Bedrosian I (2016) Contralateral prophylactic mastectomy: current perspectives. Int J Womens Health 8:213–223PubMedPubMedCentral
21.
Zurück zum Zitat Offodile AC 2nd, Hwang ES, Greenup RA (2020) Contralateral prophylactic mastectomy in the era of financial toxicity: an additional point for concern? Ann Surg 271(5):817–818PubMed Offodile AC 2nd, Hwang ES, Greenup RA (2020) Contralateral prophylactic mastectomy in the era of financial toxicity: an additional point for concern? Ann Surg 271(5):817–818PubMed
22.
Zurück zum Zitat Regenbogen SE, Veenstra CM, Hawley ST et al (2014) The personal financial burden of complications after colorectal cancer surgery. Cancer 120:3074–3081PubMed Regenbogen SE, Veenstra CM, Hawley ST et al (2014) The personal financial burden of complications after colorectal cancer surgery. Cancer 120:3074–3081PubMed
23.
Zurück zum Zitat Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML (2011) Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst 103:117–128PubMedPubMedCentral Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML (2011) Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst 103:117–128PubMedPubMedCentral
24.
Zurück zum Zitat Lentz R, Benson AB 3rd, Kircher S (2019) Financial toxicity in cancer care: Prevalence, causes, consequences, and reduction strategies. J Surg Oncol 120:85–92PubMed Lentz R, Benson AB 3rd, Kircher S (2019) Financial toxicity in cancer care: Prevalence, causes, consequences, and reduction strategies. J Surg Oncol 120:85–92PubMed
25.
Zurück zum Zitat Gordon LG, Merollini KMD, Lowe A, Chan RJ (2017) A systematic review of financial toxicity among cancer survivors: we can't pay the co-pay. Patient 10:295–309PubMed Gordon LG, Merollini KMD, Lowe A, Chan RJ (2017) A systematic review of financial toxicity among cancer survivors: we can't pay the co-pay. Patient 10:295–309PubMed
26.
Zurück zum Zitat Zafar SY, Peppercorn JM, Schrag D et al (2013) The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience. Oncologist 18:381–390PubMedPubMedCentral Zafar SY, Peppercorn JM, Schrag D et al (2013) The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience. Oncologist 18:381–390PubMedPubMedCentral
27.
Zurück zum Zitat Zafar SY, Abernethy AP (2013) Financial toxicity, Part I: a new name for a growing problem. Oncology (Williston Park) 27:80–149 Zafar SY, Abernethy AP (2013) Financial toxicity, Part I: a new name for a growing problem. Oncology (Williston Park) 27:80–149
28.
Zurück zum Zitat Zafar SY, McNeil RB, Thomas CM, Lathan CS, Ayanian JZ, Provenzale D (2015) Population-based assessment of cancer survivors' financial burden and quality of life: a prospective cohort study. J Oncol Pract 11:145–150PubMed Zafar SY, McNeil RB, Thomas CM, Lathan CS, Ayanian JZ, Provenzale D (2015) Population-based assessment of cancer survivors' financial burden and quality of life: a prospective cohort study. J Oncol Pract 11:145–150PubMed
29.
Zurück zum Zitat Ell K, Xie B, Wells A, Nedjat-Haiem F, Lee PJ, Vourlekis B (2008) Economic stress among low-income women with cancer: effects on quality of life. Cancer 112:616–625PubMed Ell K, Xie B, Wells A, Nedjat-Haiem F, Lee PJ, Vourlekis B (2008) Economic stress among low-income women with cancer: effects on quality of life. Cancer 112:616–625PubMed
30.
Zurück zum Zitat Fenn KM, Evans SB, McCorkle R et al (2014) Impact of financial burden of cancer on survivors' quality of life. J Oncol Pract 10:332–338PubMed Fenn KM, Evans SB, McCorkle R et al (2014) Impact of financial burden of cancer on survivors' quality of life. J Oncol Pract 10:332–338PubMed
31.
Zurück zum Zitat Ramsey SD, Bansal A, Fedorenko CR et al (2016) Financial insolvency as a risk factor for early mortality among patients with cancer. J Clin Oncol 34:980–986PubMedPubMedCentral Ramsey SD, Bansal A, Fedorenko CR et al (2016) Financial insolvency as a risk factor for early mortality among patients with cancer. J Clin Oncol 34:980–986PubMedPubMedCentral
32.
Zurück zum Zitat Greenup RA, Rushing C, Fish L et al (2019) Financial costs and burden related to decisions for breast cancer surgery. J Oncol Pract 15:e666–e676PubMedPubMedCentral Greenup RA, Rushing C, Fish L et al (2019) Financial costs and burden related to decisions for breast cancer surgery. J Oncol Pract 15:e666–e676PubMedPubMedCentral
33.
Zurück zum Zitat Jagsi R, Pottow JAE, Griffith KA et al (2014) Long-term financial burden of breast cancer: experiences of a diverse cohort of survivors identified through population-based registries. J Clin Oncol 32:1269–1276PubMedPubMedCentral Jagsi R, Pottow JAE, Griffith KA et al (2014) Long-term financial burden of breast cancer: experiences of a diverse cohort of survivors identified through population-based registries. J Clin Oncol 32:1269–1276PubMedPubMedCentral
34.
Zurück zum Zitat Rosenzweig M, West M, Matthews J et al (2019) Financial toxicity among women with metastatic breast cancer. Oncol Nurs Forum 46:83–91PubMed Rosenzweig M, West M, Matthews J et al (2019) Financial toxicity among women with metastatic breast cancer. Oncol Nurs Forum 46:83–91PubMed
35.
Zurück zum Zitat de Souza JA, Yap BJ, Hlubocky FJ et al (2014) The development of a financial toxicity patient-reported outcome in cancer: The COST measure. Cancer 120:3245–3253PubMed de Souza JA, Yap BJ, Hlubocky FJ et al (2014) The development of a financial toxicity patient-reported outcome in cancer: The COST measure. Cancer 120:3245–3253PubMed
36.
Zurück zum Zitat de Souza JA, Yap BJ, Wroblewski K et al (2017) Measuring financial toxicity as a clinically relevant patient-reported outcome: the validation of the COmprehensive Score for financial Toxicity (COST). Cancer 123:476–484PubMed de Souza JA, Yap BJ, Wroblewski K et al (2017) Measuring financial toxicity as a clinically relevant patient-reported outcome: the validation of the COmprehensive Score for financial Toxicity (COST). Cancer 123:476–484PubMed
38.
Zurück zum Zitat Ware J Jr, Kosinski M, Keller SD (1996) A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 34:220–233PubMed Ware J Jr, Kosinski M, Keller SD (1996) A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 34:220–233PubMed
39.
Zurück zum Zitat Ware JE, Keller SD, Kosinski M (1995) SF-12: how to score the SF-12 physical and mental health summary scales. Health Institute, New England Medical Center, Boston Ware JE, Keller SD, Kosinski M (1995) SF-12: how to score the SF-12 physical and mental health summary scales. Health Institute, New England Medical Center, Boston
40.
Zurück zum Zitat Dindo D, Demartines N, Clavien P-A (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205–213PubMedPubMedCentral Dindo D, Demartines N, Clavien P-A (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205–213PubMedPubMedCentral
41.
Zurück zum Zitat Hazell SZ, Fu W, Hu C et al (2020) Financial toxicity in lung cancer: an assessment of magnitude, perception, and impact on quality of life. Ann Oncol 31:96–102PubMed Hazell SZ, Fu W, Hu C et al (2020) Financial toxicity in lung cancer: an assessment of magnitude, perception, and impact on quality of life. Ann Oncol 31:96–102PubMed
42.
Zurück zum Zitat Casilla-Lennon MM, Choi SK, Deal AM et al (2018) Financial toxicity among patients with bladder cancer: reasons for delay in care and effect on quality of life. J Urol 199:1166–1173PubMed Casilla-Lennon MM, Choi SK, Deal AM et al (2018) Financial toxicity among patients with bladder cancer: reasons for delay in care and effect on quality of life. J Urol 199:1166–1173PubMed
45.
Zurück zum Zitat Huang J, Chagpar A (2018) Impact of anticipated financial burden on patient decision to undergo contralateral prophylactic mastectomy. Surgery 164:856–865PubMed Huang J, Chagpar A (2018) Impact of anticipated financial burden on patient decision to undergo contralateral prophylactic mastectomy. Surgery 164:856–865PubMed
46.
Zurück zum Zitat Hwang ES, Locklear TD, Rushing CN et al (2016) Patient-Reported Outcomes After Choice for Contralateral Prophylactic Mastectomy. J Clin Oncol 34:1518–1527PubMed Hwang ES, Locklear TD, Rushing CN et al (2016) Patient-Reported Outcomes After Choice for Contralateral Prophylactic Mastectomy. J Clin Oncol 34:1518–1527PubMed
47.
Zurück zum Zitat Koslow S, Pharmer LA, Scott AM et al (2013) Long-term patient-reported satisfaction after contralateral prophylactic mastectomy and implant reconstruction. Ann Surg Oncol 20:3422–3429PubMed Koslow S, Pharmer LA, Scott AM et al (2013) Long-term patient-reported satisfaction after contralateral prophylactic mastectomy and implant reconstruction. Ann Surg Oncol 20:3422–3429PubMed
48.
Zurück zum Zitat Momoh AO, Cohen WA, Kidwell KM et al (2017) Tradeoffs Associated With Contralateral Prophylactic Mastectomy in Women Choosing Breast Reconstruction: Results of a Prospective Multicenter Cohort. Ann Surg 266:158–164PubMed Momoh AO, Cohen WA, Kidwell KM et al (2017) Tradeoffs Associated With Contralateral Prophylactic Mastectomy in Women Choosing Breast Reconstruction: Results of a Prospective Multicenter Cohort. Ann Surg 266:158–164PubMed
49.
Zurück zum Zitat Kuykendall LV, Tugertimur B, Agoris C, Bijan S, Kumar A, Dayicioglu D (2017) Unilateral Versus Bilateral Breast Reconstruction: Is Less Really More? Ann Plast Surg 78:S275–s278PubMed Kuykendall LV, Tugertimur B, Agoris C, Bijan S, Kumar A, Dayicioglu D (2017) Unilateral Versus Bilateral Breast Reconstruction: Is Less Really More? Ann Plast Surg 78:S275–s278PubMed
50.
Zurück zum Zitat Buchanan PJ, Abdulghani M, Waljee JF et al (2016) An Analysis of the Decisions Made for Contralateral Prophylactic Mastectomy and Breast Reconstruction. Plast Reconstr Surg 138:29–40PubMed Buchanan PJ, Abdulghani M, Waljee JF et al (2016) An Analysis of the Decisions Made for Contralateral Prophylactic Mastectomy and Breast Reconstruction. Plast Reconstr Surg 138:29–40PubMed
51.
Zurück zum Zitat Geiger AM, West CN, Nekhlyudov L et al (2006) Contentment with quality of life among breast cancer survivors with and without contralateral prophylactic mastectomy. J Clin Oncol 24:1350–1356PubMed Geiger AM, West CN, Nekhlyudov L et al (2006) Contentment with quality of life among breast cancer survivors with and without contralateral prophylactic mastectomy. J Clin Oncol 24:1350–1356PubMed
52.
Zurück zum Zitat Frost MH, Hoskin TL, Hartmann LC, Degnim AC, Johnson JL, Boughey JC (2011) Contralateral prophylactic mastectomy: long-term consistency of satisfaction and adverse effects and the significance of informed decision-making, quality of life, and personality traits. Ann Surg Oncol 18:3110–3116PubMedPubMedCentral Frost MH, Hoskin TL, Hartmann LC, Degnim AC, Johnson JL, Boughey JC (2011) Contralateral prophylactic mastectomy: long-term consistency of satisfaction and adverse effects and the significance of informed decision-making, quality of life, and personality traits. Ann Surg Oncol 18:3110–3116PubMedPubMedCentral
53.
Zurück zum Zitat Unukovych D, Sandelin K, Liljegren A et al (2012) Contralateral prophylactic mastectomy in breast cancer patients with a family history: a prospective 2-years follow-up study of health related quality of life, sexuality and body image. Eur J Cancer 48:3150–3156PubMed Unukovych D, Sandelin K, Liljegren A et al (2012) Contralateral prophylactic mastectomy in breast cancer patients with a family history: a prospective 2-years follow-up study of health related quality of life, sexuality and body image. Eur J Cancer 48:3150–3156PubMed
55.
Zurück zum Zitat Altschuler A, Nekhlyudov L, Rolnick SJ et al (2008) Positive, negative, and disparate–women's differing long-term psychosocial experiences of bilateral or contralateral prophylactic mastectomy. Breast J 14:25–32PubMed Altschuler A, Nekhlyudov L, Rolnick SJ et al (2008) Positive, negative, and disparate–women's differing long-term psychosocial experiences of bilateral or contralateral prophylactic mastectomy. Breast J 14:25–32PubMed
56.
Zurück zum Zitat Montgomery LL, Tran KN, Heelan MC et al (1999) Issues of regret in women with contralateral prophylactic mastectomies. Ann Surg Oncol 6:546–552PubMed Montgomery LL, Tran KN, Heelan MC et al (1999) Issues of regret in women with contralateral prophylactic mastectomies. Ann Surg Oncol 6:546–552PubMed
57.
Zurück zum Zitat Beesley H, Holcombe C, Brown SL, Salmon P (2013) Risk, worry and cosmesis in decision-making for contralateral risk-reducing mastectomy: analysis of 60 consecutive cases in a specialist breast unit. Breast 22:179–184PubMed Beesley H, Holcombe C, Brown SL, Salmon P (2013) Risk, worry and cosmesis in decision-making for contralateral risk-reducing mastectomy: analysis of 60 consecutive cases in a specialist breast unit. Breast 22:179–184PubMed
58.
Zurück zum Zitat Rosenberg SM, Sepucha K, Ruddy KJ et al (2015) Local therapy decision-making and contralateral prophylactic mastectomy in young women with early-stage breast cancer. Ann Surg Oncol 22:3809–3815PubMedPubMedCentral Rosenberg SM, Sepucha K, Ruddy KJ et al (2015) Local therapy decision-making and contralateral prophylactic mastectomy in young women with early-stage breast cancer. Ann Surg Oncol 22:3809–3815PubMedPubMedCentral
59.
Zurück zum Zitat Silva AK, Lapin B, Yao KA, Song DH, Sisco M (2015) The effect of contralateral prophylactic mastectomy on perioperative complications in women undergoing immediate breast reconstruction: a NSQIP analysis. Ann Surg Oncol 22:3474–3480PubMed Silva AK, Lapin B, Yao KA, Song DH, Sisco M (2015) The effect of contralateral prophylactic mastectomy on perioperative complications in women undergoing immediate breast reconstruction: a NSQIP analysis. Ann Surg Oncol 22:3474–3480PubMed
60.
Zurück zum Zitat Eck DL, Perdikis G, Rawal B, Bagaria S, McLaughlin SA (2014) Incremental risk associated with contralateral prophylactic mastectomy and the effect on adjuvant therapy. Ann Surg Oncol 21:3297–3303PubMed Eck DL, Perdikis G, Rawal B, Bagaria S, McLaughlin SA (2014) Incremental risk associated with contralateral prophylactic mastectomy and the effect on adjuvant therapy. Ann Surg Oncol 21:3297–3303PubMed
61.
Zurück zum Zitat Nekhlyudov L, Bower M, Herrinton LJ et al (2005) Women's decision-making roles regarding contralateral prophylactic mastectomy. J Natl Cancer Inst Monogr. 2005:55–60 Nekhlyudov L, Bower M, Herrinton LJ et al (2005) Women's decision-making roles regarding contralateral prophylactic mastectomy. J Natl Cancer Inst Monogr. 2005:55–60
62.
Zurück zum Zitat Covelli AM, Baxter NN, Fitch MI, McCready DR, Wright FC (2015) 'Taking control of cancer': understanding women's choice for mastectomy. Ann Surg Oncol 22:383–391PubMed Covelli AM, Baxter NN, Fitch MI, McCready DR, Wright FC (2015) 'Taking control of cancer': understanding women's choice for mastectomy. Ann Surg Oncol 22:383–391PubMed
63.
Zurück zum Zitat Rosenberg SM, Partridge AH (2014) Contralateral prophylactic mastectomy: an opportunity for shared decision making. JAMA Surg 149:589–590PubMedPubMedCentral Rosenberg SM, Partridge AH (2014) Contralateral prophylactic mastectomy: an opportunity for shared decision making. JAMA Surg 149:589–590PubMedPubMedCentral
64.
Zurück zum Zitat Greenup RA, Rushing CN, Fish LJ et al (2019) Perspectives on the costs of cancer care: a survey of the american society of breast surgeons. Ann Surg Oncol 26:3141–3151PubMedPubMedCentral Greenup RA, Rushing CN, Fish LJ et al (2019) Perspectives on the costs of cancer care: a survey of the american society of breast surgeons. Ann Surg Oncol 26:3141–3151PubMedPubMedCentral
65.
Zurück zum Zitat Meropol NJ, Schrag D, Smith TJ et al (2009) American Society of clinical oncology guidance statement: the cost of cancer care. J Clin Oncol 27:3868–3874PubMed Meropol NJ, Schrag D, Smith TJ et al (2009) American Society of clinical oncology guidance statement: the cost of cancer care. J Clin Oncol 27:3868–3874PubMed
66.
Zurück zum Zitat Hunter WG, Zafar SY, Hesson A et al (2017) Discussing health care expenses in the oncology clinic: analysis of cost conversations in outpatient encounters. J Oncol Pract 13:e944–e956PubMedPubMedCentral Hunter WG, Zafar SY, Hesson A et al (2017) Discussing health care expenses in the oncology clinic: analysis of cost conversations in outpatient encounters. J Oncol Pract 13:e944–e956PubMedPubMedCentral
Metadaten
Titel
Financial toxicity and contralateral prophylactic mastectomy: an analysis using propensity score methods
verfasst von
Malke Asaad
Stefanos Boukovalas
Carrie K. Chu
Yu-Li Lin
Cristina M. Checka
Mark W. Clemens
Rachel A. Greenup
Anaeze C. Offodile II
Publikationsdatum
20.07.2020
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2020
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-020-05805-0

Weitere Artikel der Ausgabe 3/2020

Breast Cancer Research and Treatment 3/2020 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.